Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma
Ehsan Malek(Roswell Park Comprehensive Cancer Center), James J. Driscoll(University Hospitals of Cleveland)
Cited by 56
Related Papers
Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma
|Oncotarget|2014|80
MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib
|Leukemia|2014|78
Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells
|Oncotarget|2014|43